VIP and CIRS — what the mold illness research has explored

This is the territory that Chronic Inflammatory Response Syndrome occupies — a territory where patients report profound and debilitating symptoms, where the clinical markers exist and can be measured, and where the standard medical system frequently has no framework to organize what it's seeing.

CIRS as a clinical construct was developed and popularized by Ritchie Shoemaker, a Maryland family physician who began seeing patients in the late 1990s with a cluster of symptoms he couldn't explain through conventional diagnoses. The initial cases involved exposure to Pfiesteria, a dinoflagellate toxin in the Chesapeake Bay. Over time, his clinical lens expanded to include biotoxins from water-damaged building molds — primarily from the Stachybotrys and Chaetomium species and their mycotoxins — as well as Lyme disease and its coinfections, ciguatera fish poisoning, and other biotoxin sources. What these patients shared, Shoemaker proposed, was not an infection per se but a maladaptive immune response: a failure to clear biotoxin exposures normally, driven by a genetic predisposition in the HLA-DR immune recognition genes, leading to a sustained inflammatory state that persisted long after the exposure itself.

The proposed mechanism is more specific than general inflammation. In Shoemaker's framework, people with susceptible HLA-DR haplotypes lack the immune recognition machinery to effectively tag and clear certain biotoxins for elimination. The toxins accumulate and continue triggering innate immune pathways. The result is a dysregulated cytokine environment — elevated TGF-beta-1, elevated C4a (a complement split product), low VIP, abnormal ADH and osmolality, dysregulated MMP-9 — and a cascade of downstream effects on pituitary hormone regulation, vasoregulation, neurological function, and immune balance. The symptom picture that patients describe — fatigue, cognitive dysfunction, autonomic instability, multiple chemical sensitivities, mood changes, sleep disruption, musculoskeletal pain — is what this dysregulated state produces when it persists.

It is essential to say clearly: CIRS as defined by Shoemaker is not a recognized diagnosis in mainstream medicine. Mainstream medical organizations have not validated the specific diagnostic criteria or the biomarker panel as a clinical standard. There are physicians who take this framework seriously and others who regard it as poorly supported. The research base consists largely of Shoemaker's own publications and the observations of the clinicians who have adopted his protocol — it is not built on the independent replication and large-scale randomized controlled trial data that mainstream medicine requires before recognizing a new diagnostic entity. This does not mean the patients are not sick. Many of them clearly are. It means the evidentiary standard for the specific mechanism proposed has not been met in the way that clinical medicine typically requires.

Within that context, the Shoemaker protocol represents a structured sequential approach to treatment that has been followed by thousands of patients and the providers who work with them. The sequence matters to its logic: first, removal from the moldy environment, because nothing downstream works if the exposure continues. Then cholestyramine, a bile acid sequestrant that binds biotoxins in the gut and facilitates elimination through the digestive tract. Then, if needed, antifungal treatment to address ongoing fungal colonization. Then hormonal and immunological correction — addressing ADH dysregulation, correcting androgen and estrogen imbalances that the inflammatory state has disrupted, addressing MMP-9 with VIP inhibitors, and using vasoactive intestinal peptide in the later phases.

VIP enters the Shoemaker protocol as something like a final regulatory reset. The hypothesis is that by the time patients have completed the earlier stages — biotoxin removal, cholestyramine binding, hormonal correction — the underlying immune state has been addressed enough that VIP can do what it's designed to do: restore regulatory balance that the sustained inflammatory response has disrupted. Shoemaker proposed, and has published clinical observations suggesting, that intranasal VIP administration at this stage can help normalize elevated TGF-beta-1, reduce C4a elevations, support ADH normalization, and address the vasoregulatory dysregulation that produces many of the symptom domains CIRS patients report.

The intranasal route is significant. Inhaled or intranasally delivered VIP reaches the nasal mucosa and may travel via the olfactory epithelium toward the central nervous system — this is one of the relatively few routes by which peptides can approach CNS tissue without the full barrier imposed by the blood-brain barrier on systemic circulation. Intranasal VIP has been used in other research contexts for its CNS and autonomic effects. In the CIRS protocol, it is used at low doses, typically multiple times daily, titrated upward as tolerated.

The evidence for this specific application is observational. Shoemaker has published case series and retrospective analyses. The biomarker data — showing movement in TGF-beta-1, C4a, VIP levels — is clinically interesting. It is not the same as a randomized controlled trial showing that patients who received VIP at this stage of the protocol fared better than those who did not, controlling for all the other interventions that preceded it. The honest assessment is that the mechanism is plausible, the clinical observations are consistent, and the evidence quality is below what mainstream medicine would require to recommend VIP for CIRS.

Among the observations that Shoemaker and clinicians working in his framework have described is that VIP appears to address a vasoregulatory dimension of CIRS that the earlier protocol steps do not fully resolve. Some CIRS patients, even after biotoxin removal and cholestyramine, continue to experience symptoms consistent with autonomic dysregulation — orthostatic intolerance, exercise intolerance, the cognitive symptoms that worsen with exertion. The hypothesis is that VIP's effects on vascular tone, pulmonary circulation, and neuroregulation address this residual component. Whether this represents a genuine mechanistic contribution from VIP or an artifact of clinical observation without adequate controls is genuinely uncertain.

It is also worth understanding why low VIP became one of the markers in the CIRS biomarker panel in the first place. In Shoemaker's clinical work, patients with CIRS consistently showed low circulating VIP levels on testing. The explanation proposed is that the sustained inflammatory state characteristic of CIRS suppresses VIP production — inflammatory cytokines, particularly TNF-α, are known to reduce VIP gene expression in preclinical models. If this is correct, it means that VIP deficiency is not just a correlation in CIRS but part of the pathophysiological mechanism — a downward spiral in which inflammation suppresses VIP, and reduced VIP removes a natural anti-inflammatory check, allowing inflammation to continue. Administering exogenous VIP in this model would be correcting a deficiency, not adding a pharmacological agent.

This framing is compelling, and it is also worth noting that it comes almost entirely from within the Shoemaker research ecosystem. The measurement of VIP in serum as a clinically meaningful marker has not been independently validated in mainstream immunology literature in the way the framework requires. The normative ranges used, the clinical significance assigned to low levels, the expected response to treatment — these are clinical conventions within the Shoemaker framework, not established standards across the field.

What the mold illness and CIRS community has undeniably contributed is a framework for thinking about a class of patient experience that mainstream medicine has largely failed to explain: the patient who becomes profoundly unwell after living or working in a water-damaged building, whose symptoms are real and measurable but don't fit standard diagnostic categories, who has typically seen multiple specialists without satisfactory explanation, and who has often been told that their symptoms are psychological. Whether the specific mechanism that Shoemaker has proposed is correct in every detail matters less, in some ways, than the observation that these patients exist, that their suffering is real, and that the clinical interventions in this framework — including VIP — have helped a meaningful number of them in ways that conventional medicine was not offering.

The broader question that CIRS raises is a structural one about how medicine responds when a significant population of patients presents with credible suffering and the explanatory framework available either doesn't fit or hasn't been validated. The standard response — waiting for adequate RCT evidence before acknowledging the diagnosis — has real costs when the patients experiencing the gap are living in it. The alternative — validating a framework before it has been rigorously tested — has different costs. Clinicians working in this space are navigating that tension every day, and VIP is one of the tools they have chosen to use while the evidentiary debate continues.

For people exploring this territory, the practical reality is that VIP in the CIRS context is used off-label, is not FDA-approved for this indication, and requires working with a provider who is familiar with the protocol and can evaluate the relevant biomarkers, guide the sequencing, and monitor for the adverse effects — primarily nasal irritation, occasional GI symptoms, and the rare orthostatic reactions that some patients report at higher doses. It is not a first step. It is a late-stage intervention within a broader protocol that begins with removing the exposure and proceeds through multiple phases before VIP enters the picture. Understanding that sequencing is not optional — it is the framework within which the clinical observations have been made.

The research is ongoing. The evidentiary debates are real. The patients are navigating both.